Evidence map›Paper›PMID 31010626›Full record

ArticleOral oncology2019

Development of a cytology-based multivariate analytical risk index for oral cancer.

Timothy J Abram, Pierre N Floriano, Robert James, A Ross Kerr, Martin H Thornhill, Spencer W Redding, Nadarajah Vigneswaran, Rameez Raja, Michael P McRae, John T McDevitt

Abstract read
In one paragraph

Article in Oral oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. A brief review of cytology in dentistry.British dental journal · 2024
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Timothy J AbramRice University, Department of Bioengineering, Houston, TX, USA.
Pierre N FlorianoRice University, Department of Bioengineering, Houston, TX, USA; NeoTherma Oncology, Houston, TX, USA.
Robert JamesRho Inc., Chapel Hill, NC, USA. Electronic address: robert_james@rhoworld.com.
A Ross KerrNew York University College of Dentistry, Department of Oral and Maxillofacial Pathology, Radiology & Medicine, New York, NY, USA.
Martin H ThornhillDepartment of Oral & Maxillofacial Medicine, Surgery and Pathology, School of Clinical Dentistry, University of Sheffield, Sheffield, UK.
Spencer W ReddingThe University of Texas Health Science Center at San Antonio, Department of Comprehensive Dentistry and Mays Cancer Center, San Antonio, TX, USA.
Nadarajah VigneswaranThe University of Texas Health Science Center at Houston, Department of Diagnostic and Biomedical Sciences, Houston, TX, USA.
Rameez RajaRice University, Department of Bioengineering, Houston, TX, USA.
Michael P McRaeRice University, Department of Bioengineering, Houston, TX, USA; Department of Biomaterials, Bioengineering Institute, New York University, 433 First Avenue, Room 820, New York, NY 10010-4086, USA.
John T McDevittRice University, Department of Bioengineering, Houston, TX, USA; Department of Biomaterials, Bioengineering Institute, New York University, 433 First Avenue, Room 820, New York, NY 10010-4086, USA. Electronic address: mcdevitt@nyu.edu.

Funding

Monitoring of Oral Cancer Patients Using Novel Lab-on-a-Chip EnsemblesRC2DE020785 · NIDCR · RICE UNIVERSITY · PI MCDEVITT, JOHN T · 2009 to 2012
$3.5M
NIDCR NIH HHS RC2 DE020785
6 · The paper itself

Abstract

objectivesThe diagnosis and management of oral cavity cancers are often complicated by the uncertainty of which patients will undergo malignant transformation, obligating close surveillance over time. However, serial biopsies are undesirable, highly invasive, and subject to inherent issues with poor inter-pathologist agreement and unpredictability as a surrogate for malignant transformation and clinical outcomes. The goal of this study was to develop and evaluate a Multivariate Analytical Risk Index for Oral Cancer (MARIO) with potential to provide non-invasive, sensitive, and quantitative risk assessments for monitoring lesion progression. MATERIALS AND

methodsA series of predictive models were developed and validated using previously recorded single-cell data from oral cytology samples resulting in a "continuous risk score". Model development consisted of: (1) training base classification models for each diagnostic class pair, (2) pairwise coupling to obtain diagnostic class probabilities, and (3) a weighted aggregation resulting in a continuous MARIO. RESULTS AND

conclusionsDiagnostic accuracy based on optimized cut-points for the test dataset ranged from 76.0% for Benign, to 82.4% for Dysplastic, 89.6% for Malignant, and 97.6% for Normal controls for an overall MARIO accuracy of 72.8%. Furthermore, a strong positive relationship with diagnostic severity was demonstrated (Pearson's coefficient = 0.805 for test dataset) as well as the ability of the MARIO to respond to subtle changes in cell composition. The development of a continuous MARIO for PMOL is presented, resulting in a sensitive, accurate, and non-invasive method with potential for enabling monitoring disease progression, recurrence, and the need for therapeutic intervention of these lesions.

Indexed as

CytodiagnosisBiopsyHumansLab-On-A-Chip DevicesMouth NeoplasmsMultivariate AnalysisNeoplasm GradingNeoplasm StagingReproducibility of ResultsRisk AssessmentCytologyModel ensemblesMulti-class classificationOral cancerRisk assessment

Identifiers

PMID31010626
PMCPMC7358989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.